TCRX Tscan Therapeutics Inc
Company Analysis
Latest News
🔴 Tscan Therapeutics is trading 5.4% down in pre-market after pausing Phase 3 ALLOHA-2 enrollment
Tscan Therapeutics is trading 5.4% down in pre-market at $0.36 after announcing on September 2, 2026, that it would pause further enrollment in the Phase 3...
TScan Therapeutics Announces Restructuring, Cuts 75% of Workforce to Focus on Solid Tumors
TScan Therapeutics announced a significant strategic reorganization to prioritize its preclinical in vivo solid tumor program and extend its cash runway. The...
TScan Slashes 75% of Its Staff and Freezes Its Most Advanced Trial — Can a Pivot to Solid Tumors Save a Sub-$1 Stock?
Shares of TScan Therapeutics (TCRX) cratered 25.7% to $0.49 on September 2 after the Waltham, Mass., biotech announced it would gut three-quarters of its...
🔴 Tscan Therapeutics is trading 26% down today after pausing Phase 3 ALLOHA-2 enrollment
Tscan Therapeutics is trading 25.71% down now at $0.49 after announcing a strategic reorganization on September 2, 2026, including a pause in Phase 3 ALLOHA-2...
TScan Therapeutics Slashes Staff by 75%, Prioritizing Solid Tumor Pipeline
TScan Therapeutics is cutting its workforce by approximately 75% to prioritize its in vivo solid tumor program. The company is currently advancing two product...
🔴 Tscan Therapeutics is trading 14% down in pre-market
Tscan Therapeutics is trading at $0.57, down -13.72%, with no clear company-specific catalyst identified for September 2, 2026. - No fresh company-specific...
🔴 Tscan Therapeutics is trading 8.43% down in pre-market with no fresh company-specific catalyst
Tscan Therapeutics is trading at $0.61, down -8.43% in pre-market, with no fresh company-specific catalyst identified for September 2, 2026. - The latest...
🟢 Tscan Therapeutics is trading 5.7% up in pre-market
Tscan Therapeutics is trading at $0.70, up +5.67% in pre-market, with no fresh company-specific catalyst identified. - No announcement, earnings release, or...
🔴 Tscan Therapeutics Inc is trading 5.69% down
TCRX is trading at $0.69, down 5.69%.
🟢 Tscan Therapeutics is trading 5% up today amid volatility, with no confirmed catalyst
Tscan Therapeutics is trading 5.13% up now at $0.79, with the move appearing primarily volatility-driven rather than tied to a confirmed fundamental...
🟢 Tscan Therapeutics is trading 5% up in after-hours trading amid volatility after prior selloff
Tscan Therapeutics is trading at $0.79, up +5.04% in after-hours trading; the move may reflect volatility after the prior selloff, as no separate bullish...
🔴 Tscan Therapeutics is trading 6.21% down today after Amgen terminated collaboration and license agreement
Tscan Therapeutics is trading 6.21% down at $0.77 after an August 18, 2026 filing disclosed that Amgen elected to terminate its research collaboration and...
🔴 Tscan Therapeutics is trading 5.4% down in pre-market amid elevated Treasury yields
Tscan Therapeutics is trading 5.42% down now at $0.78 as broader risk-off pressure weighs on growth-oriented stocks. - No new company-specific announcement,...
🔴 Tscan Therapeutics is trading 5.53% down in after-hours trading as rising Treasury yields pressure growth stocks
Tscan Therapeutics is trading 5.53% down now at $0.78 as broad risk-off selling pressures U.S. equities on August 18, 2026. - No new company-specific...
🟢 Tscan Therapeutics is trading 5.6% up today despite no clear company-specific catalyst
Tscan Therapeutics is trading at $0.83, up 5.64%, with no clear company-specific announcement, filing, analyst action, or clinical catalyst identified for...
Tscan Therapeutics maintains Buy rating, despite going concern and cash risks
H.C. Wainwright reiterated its Buy rating for Tscan Therapeutics on August 13, 2026. The firm issued this update one day after Tscan released its...
TScan Therapeutics second quarter 2026 loss narrows as pivotal Phase 3 study begins
TScan Therapeutics reported a narrowed net loss of $30.4 million for the second quarter of 2026, primarily driven by a $9.2 million reduction in R&D expenses....
Tscan Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Tscan Therapeutics is expected to report a Q2 2026 loss of $0.29 per share on revenue of $1.88 million, with the stock currently trading at $0.80 against a...
🟢 Tscan Therapeutics is trading 5.2% up today amid a broader biotech rally
Tscan Therapeutics is trading 5.2% up at $0.77 today, appearing to follow a broader bid in the biotech sector and constructive overall market sentiment rather...
🟢 Tscan Therapeutics is trading 3.9% up today after dosing first patient in Phase 3 ALLOHA-2 trial
Tscan Therapeutics is trading 3.9% up at $0.79 today after announcing the first patient dosing of its lead T-cell therapy, TSC-101, in the pivotal Phase 3...